^
TP53 mutation
|
CLL
|
TP53 mutation
|
CLL
|
BR Resistant: B - Late Trials
ASH 2021 - 3 weeks
|
BR Resistant: B - Late Trials
ASH 2021 - 3 weeks
|
TP53 mutation
|
CLL
|
TP53 mutation
|
CLL
|
ICP-022 Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
|
ICP-022 Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
ICP-022 Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
|
ICP-022 Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
|
Chr del(11q)
|
CLL
|
Chr del(11q)
|
CLL
|
ICP-022 Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
|
ICP-022 Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
|
BTK C481
|
CLL
|
BTK C481
|
CLL
|
LOXO-305 Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
|
LOXO-305 Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
|
SF3B1 mutation
|
CLL
|
SF3B1 mutation
|
CLL
|
obinutuzumab + GS-9973 Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
|
obinutuzumab + GS-9973 Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
|
NOTCH1 mutation
|
CLL
|
NOTCH1 mutation
|
CLL
|
obinutuzumab + GS-9973 Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
|
obinutuzumab + GS-9973 Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
|
TP53 mutation
|
CLL
|
TP53 mutation
|
CLL
|
obinutuzumab + GS-9973 Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
|
obinutuzumab + GS-9973 Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
|
LGALS1 overexpression + LAG3 overexpression
|
CLL
|
LGALS1 overexpression + LAG3 overexpression
|
CLL
|
ibrutinib Resistant: C3 – Early Trials
ASH 2021 - 3 weeks
|
ibrutinib Resistant: C3 – Early Trials
ASH 2021 - 3 weeks
|
LGALS1 overexpression + LAG3 overexpression
|
CLL
|
LGALS1 overexpression + LAG3 overexpression
|
CLL
|
OTX-008 Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
|
OTX-008 Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
|
PTEN underexpression
|
CLL
|
PTEN underexpression
|
CLL
|
ibrutinib Resistant: C3 – Early Trials
Cell Death Dis - 3 weeks
|
ibrutinib Resistant: C3 – Early Trials
Cell Death Dis - 3 weeks
|
miR-543 overexpression
|
CLL
|
miR-543 overexpression
|
CLL
|
ibrutinib Resistant: C3 – Early Trials
Cell Death Dis - 3 weeks
|
ibrutinib Resistant: C3 – Early Trials
Cell Death Dis - 3 weeks
|
miR-494 overexpression
|
CLL
|
miR-494 overexpression
|
CLL
|
ibrutinib Resistant: C3 – Early Trials
Cell Death Dis - 3 weeks
|
ibrutinib Resistant: C3 – Early Trials
Cell Death Dis - 3 weeks
|
miR-495 overexpression
|
CLL
|
miR-495 overexpression
|
CLL
|
ibrutinib Resistant: C3 – Early Trials
Cell Death Dis - 3 weeks
|
ibrutinib Resistant: C3 – Early Trials
Cell Death Dis - 3 weeks
|
TP53 mutation
|
CLL
|
TP53 mutation
|
CLL
|
BTK inhibitor Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
|
BTK inhibitor Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
BTK inhibitor Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
|
BTK inhibitor Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
|
LY9 expression
|
CLL
|
LY9 expression
|
CLL
|
CAR-T immunotherapy Sensitive: D – Preclinical
ASH 2021 - 3 weeks
|
CAR-T immunotherapy Sensitive: D – Preclinical
ASH 2021 - 3 weeks
|
CD20 positive
|
CLL
|
CD20 positive
|
CLL
|
Truxima (rituximab biosimilar) Sensitive: A1 - Approval
|
Truxima (rituximab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
ibrutinib + rituximab Sensitive: A1 - Approval
|
ibrutinib + rituximab Sensitive: A1 - Approval
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
venetoclax + obinutuzumab Sensitive: A1 - Approval
|
venetoclax + obinutuzumab Sensitive: A1 - Approval
|
TP53 mutation
|
CLL
|
TP53 mutation
|
CLL
|
venetoclax + obinutuzumab Sensitive: A1 - Approval
|
venetoclax + obinutuzumab Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
venetoclax + obinutuzumab Sensitive: A1 - Approval
|
venetoclax + obinutuzumab Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
ICP-022 Sensitive: A1 - Approval
|
ICP-022 Sensitive: A1 - Approval
|
CD20 expression
|
CLL
|
CD20 expression
|
CLL
|
rituximab-arrx Sensitive: A1 - Approval
|
rituximab-arrx Sensitive: A1 - Approval
|
TP53 mutation
|
CLL
|
TP53 mutation
|
CLL
|
venetoclax Sensitive: A1 - Approval
|
venetoclax Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
Truxima (rituximab biosimilar) Sensitive: A1 - Approval
|
Truxima (rituximab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
Rixathon (rituximab biosimilar) Sensitive: A1 - Approval
|
Rixathon (rituximab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
Ruxience (rituximab biosimilar) Sensitive: A1 - Approval
|
Ruxience (rituximab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
venetoclax + rituximab Sensitive: A1 - Approval
|
venetoclax + rituximab Sensitive: A1 - Approval
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
venetoclax Sensitive: A1 - Approval
|
venetoclax Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
zanubrutinib Sensitive: A1 - Approval
|
zanubrutinib Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
ibrutinib Sensitive: A1 - Approval
|
ibrutinib Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
ibrutinib + obinutuzumab Sensitive: A1 - Approval
|
ibrutinib + obinutuzumab Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
obinutuzumab Sensitive: A1 - Approval
|
obinutuzumab Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
rituximab Sensitive: A1 - Approval
|
rituximab Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
ofatumumab Sensitive: A1 - Approval
|
ofatumumab Sensitive: A1 - Approval
|
CD20 positive
|
CLL
|
CD20 positive
|
CLL
|
rituximab Sensitive: A1 - Approval
|
rituximab Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
venetoclax Sensitive: A1 - Approval
|
venetoclax Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
rituximab/hyaluronidase Sensitive: A1 - Approval
|
rituximab/hyaluronidase Sensitive: A1 - Approval
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
ibrutinib Sensitive: A1 - Approval
|
ibrutinib Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
obinutuzumab + acalabrutinib Sensitive: A1 - Approval
|
obinutuzumab + acalabrutinib Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
obinutuzumab Sensitive: A1 - Approval
|
obinutuzumab Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
acalabrutinib Sensitive: A1 - Approval
|
acalabrutinib Sensitive: A1 - Approval
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
rituximab + idelalisib Sensitive: A1 - Approval
|
rituximab + idelalisib Sensitive: A1 - Approval
|
TP53 mutation
|
CLL
|
TP53 mutation
|
CLL
|
rituximab + idelalisib Sensitive: A1 - Approval
|
rituximab + idelalisib Sensitive: A1 - Approval
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
acalabrutinib Sensitive: A1 - Approval
|
acalabrutinib Sensitive: A1 - Approval
|
TP53 mutation
|
CLL
|
TP53 mutation
|
CLL
|
acalabrutinib Sensitive: A1 - Approval
|
acalabrutinib Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
alemtuzumab Sensitive: A1 - Approval
|
alemtuzumab Sensitive: A1 - Approval
|
TP53 mutation
|
CLL
|
TP53 mutation
|
CLL
|
idelalisib + ofatumumab Sensitive: A1 - Approval
|
idelalisib + ofatumumab Sensitive: A1 - Approval
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
idelalisib + ofatumumab Sensitive: A1 - Approval
|
idelalisib + ofatumumab Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
rituximab + idelalisib Sensitive: A1 - Approval
|
rituximab + idelalisib Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
duvelisib Sensitive: A1 - Approval
|
duvelisib Sensitive: A1 - Approval
|
CD20 positive
|
CLL
|
CD20 positive
|
CLL
|
Ruxience (rituximab biosimilar) Sensitive: A1 - Approval
|
Ruxience (rituximab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
bendamustine Sensitive: A1 - Approval
|
bendamustine Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
bendamustine RTD Sensitive: A1 - Approval
|
bendamustine RTD Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
PCR Sensitive: A2 - Guideline
|
PCR Sensitive: A2 - Guideline
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
ofatumumab Sensitive: A2 - Guideline
|
ofatumumab Sensitive: A2 - Guideline
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
FCR Sensitive: A2 - Guideline
|
FCR Sensitive: A2 - Guideline
|
TP53 mutation
|
CLL
|
TP53 mutation
|
CLL
|
rituximab + alemtuzumab Sensitive: A2 - Guideline
|
rituximab + alemtuzumab Sensitive: A2 - Guideline
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
rituximab Sensitive: A2 - Guideline
|
rituximab Sensitive: A2 - Guideline
|
TP53 mutation
|
CLL
|
TP53 mutation
|
CLL
|
venetoclax + rituximab Sensitive: A2 - Guideline
|
venetoclax + rituximab Sensitive: A2 - Guideline
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
venetoclax + rituximab Sensitive: A2 - Guideline
|
venetoclax + rituximab Sensitive: A2 - Guideline
|
TP53 mutation
|
CLL
|
TP53 mutation
|
CLL
|
zanubrutinib Sensitive: A2 - Guideline
|
zanubrutinib Sensitive: A2 - Guideline
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
zanubrutinib Sensitive: A2 - Guideline
|
zanubrutinib Sensitive: A2 - Guideline
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
rituximab + lenalidomide Sensitive: A2 - Guideline
|
rituximab + lenalidomide Sensitive: A2 - Guideline
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
rituximab + idelalisib Sensitive: A2 - Guideline
|
rituximab + idelalisib Sensitive: A2 - Guideline
|
Chr del(11q)
|
CLL
|
Chr del(11q)
|
CLL
|
ibrutinib Sensitive: A2 - Guideline
|
ibrutinib Sensitive: A2 - Guideline
|
Chr del(11q)
|
CLL
|
Chr del(11q)
|
CLL
|
rituximab Resistant: A2 - Guideline
|
rituximab Resistant: A2 - Guideline
|
TP53 mutation
|
CLL
|
TP53 mutation
|
CLL
|
ibrutinib Sensitive: A2 - Guideline
|
ibrutinib Sensitive: A2 - Guideline
|
TP53 mutation
|
CLL
|
TP53 mutation
|
CLL
|
ofatumumab Resistant: A2 - Guideline
|
ofatumumab Resistant: A2 - Guideline
|
TP53 mutation
|
CLL
|
TP53 mutation
|
CLL
|
idelalisib Sensitive: A2 - Guideline
|
idelalisib Sensitive: A2 - Guideline
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
idelalisib Sensitive: A2 - Guideline
|
idelalisib Sensitive: A2 - Guideline
|
IGH mutation
|
CLL
|
IGH mutation
|
CLL
|
ibrutinib Sensitive: A2 - Guideline
|
ibrutinib Sensitive: A2 - Guideline
|
IGH mutation
|
CLL
|
IGH mutation
|
CLL
|
obinutuzumab Sensitive: A2 - Guideline
|
obinutuzumab Sensitive: A2 - Guideline
|
IGH mutation
|
CLL
|
IGH mutation
|
CLL
|
venetoclax + obinutuzumab Sensitive: A2 - Guideline
|
venetoclax + obinutuzumab Sensitive: A2 - Guideline
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
chlorambucil Sensitive: A2 - Guideline
|
chlorambucil Sensitive: A2 - Guideline
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
CD20 inhibitor + bendamustine Sensitive: A2 - Guideline
|
CD20 inhibitor + bendamustine Sensitive: A2 - Guideline
|
TP53 mutation
|
CLL
|
TP53 mutation
|
CLL
|
lenalidomide Sensitive: A2 - Guideline
|
lenalidomide Sensitive: A2 - Guideline
|
TP53 mutation
|
CLL
|
TP53 mutation
|
CLL
|
rituximab + lenalidomide Sensitive: A2 - Guideline
|
rituximab + lenalidomide Sensitive: A2 - Guideline
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
lenalidomide Sensitive: A2 - Guideline
|
lenalidomide Sensitive: A2 - Guideline
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
rituximab + lenalidomide Sensitive: A2 - Guideline
|
rituximab + lenalidomide Sensitive: A2 - Guideline
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
lenalidomide Sensitive: A2 - Guideline
|
lenalidomide Sensitive: A2 - Guideline
|
TP53 deletion
|
CLL
|
TP53 deletion
|
CLL
|
idelalisib Sensitive: A2 - Guideline
|
idelalisib Sensitive: A2 - Guideline
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
idelalisib Sensitive: A2 - Guideline
|
idelalisib Sensitive: A2 - Guideline
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
rituximab + alemtuzumab Sensitive: A2 - Guideline
|
rituximab + alemtuzumab Sensitive: A2 - Guideline
|
TP53 deletion
|
CLL
|
TP53 deletion
|
CLL
|
ibrutinib Sensitive: A2 - Guideline
|
ibrutinib Sensitive: A2 - Guideline
|
TP53 deletion
|
CLL
|
TP53 deletion
|
CLL
|
rituximab Sensitive: A2 - Guideline
|
rituximab Sensitive: A2 - Guideline
|
TP53 mutation
|
CLL
|
TP53 mutation
|
CLL
|
rituximab Sensitive: A2 - Guideline
|
rituximab Sensitive: A2 - Guideline
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
alemtuzumab Sensitive: A2 - Guideline
|
alemtuzumab Sensitive: A2 - Guideline
|
TP53 mutation
|
CLL
|
TP53 mutation
|
CLL
|
alemtuzumab Sensitive: A2 - Guideline
|
alemtuzumab Sensitive: A2 - Guideline
|
TP53 mutation
|
CLL
|
TP53 mutation
|
CLL
|
pembrolizumab + nivolumab + ibrutinib Sensitive: A2 - Guideline
|
pembrolizumab + nivolumab + ibrutinib Sensitive: A2 - Guideline
|
BTK C481S
|
CLL
|
BTK C481S
|
CLL
|
acalabrutinib Resistant: A2 - Guideline
|
acalabrutinib Resistant: A2 - Guideline
|
IGH mutation
|
CLL
|
IGH mutation
|
CLL
|
FCR Sensitive: A2 - Guideline
|
FCR Sensitive: A2 - Guideline
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
nivolumab Sensitive: A2 - Guideline
|
nivolumab Sensitive: A2 - Guideline
|
Chr del(11q)
|
CLL
|
Chr del(11q)
|
CLL
|
obinutuzumab + acalabrutinib Sensitive: A2 - Guideline
|
obinutuzumab + acalabrutinib Sensitive: A2 - Guideline
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
duvelisib Sensitive: A2 - Guideline
|
duvelisib Sensitive: A2 - Guideline
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
obinutuzumab Sensitive: A2 - Guideline
|
obinutuzumab Sensitive: A2 - Guideline
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
obinutuzumab + acalabrutinib Sensitive: A2 - Guideline
|
obinutuzumab + acalabrutinib Sensitive: A2 - Guideline
|
TP53 mutation
|
CLL
|
TP53 mutation
|
CLL
|
pembrolizumab + ibrutinib Sensitive: A2 - Guideline
|
pembrolizumab + ibrutinib Sensitive: A2 - Guideline
|
TP53 mutation
|
CLL
|
TP53 mutation
|
CLL
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
TP53 mutation
|
CLL
|
TP53 mutation
|
CLL
|
nivolumab Sensitive: A2 - Guideline
|
nivolumab Sensitive: A2 - Guideline
|
TP53 mutation
|
CLL
|
TP53 mutation
|
CLL
|
duvelisib Sensitive: A2 - Guideline
|
duvelisib Sensitive: A2 - Guideline
|
TP53 mutation
|
CLL
|
TP53 mutation
|
CLL
|
obinutuzumab Sensitive: A2 - Guideline
|
obinutuzumab Sensitive: A2 - Guideline
|
TP53 mutation
|
CLL
|
TP53 mutation
|
CLL
|
obinutuzumab + acalabrutinib Sensitive: A2 - Guideline
|
obinutuzumab + acalabrutinib Sensitive: A2 - Guideline
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
rituximab + alemtuzumab Sensitive: A2 - Guideline
|
rituximab + alemtuzumab Sensitive: A2 - Guideline
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
OFAR Sensitive: A2 - Guideline
|
OFAR Sensitive: A2 - Guideline
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
R-CVAD Sensitive: A2 - Guideline
|
R-CVAD Sensitive: A2 - Guideline
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
EPOCH-R Sensitive: A2 - Guideline
|
EPOCH-R Sensitive: A2 - Guideline
|
